EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations in Mycobacterium tuberculosis

Peng Liu, Jinping Zhang, Yaqi Gong, Wenqi Liu, Guohui Xiao iD, Juan Liang, Xuan Wang, Jing Bi, Guoliang Zhang iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00165-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Peng Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Ho…. Hauptthemen laut MEDLINE: Isoniazid, Mycobacterium tuberculosis, CRISPR-Cas Systems, Antitubercular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-resistant tuberculosis (TB) is a major global public health concern. Although isoniazid is currently considered one of the most effective first-line drugs for TB treatment, its efficacy is limited by the emergence of resistance. Therefore, it is imperative to develop new methods for detecting drug-resistant TB. In this study, we developed a nucleic acid detection system based on the clustered regularly interspaced short palindromic repeat (CRISPR) Cas12a_RR protein. The system combines recombinase polymerase amplification with an engineered CRISPR/Cas12a_RR protein to enable rapid and specific detection of the katG G944C mutation in isoniazid-resistant Mycobacterium tuberculosis ( Mtb ). It could detect the target DNA at concentrations as low as 1% in a mixed sample. Compared with TaqMan quantitative polymerase chain reaction and DNA sequencing, the CRISPR/Cas12a_RR system demonstrated superior detection performance in terms of sensitivity, specificity, and cost-effectiveness. Furthermore, it effectively differentiated between drug-resistant Mtb strains from wild-type Mtb strains in clinically isolated samples, with the entire detection process completed in 60 min. In conclusion, the CRISPR/Cas12a_RR detection system offers a novel, rapid, simple, sensitive, and specific approach for identifying isoniazid-resistant Mtb , with significant potential for clinical application, particularly in resource-limited settings. IMPORTANCE This study presents a novel method for detecting isoniazid-resistant Mycobacterium tuberculosis ( Mtb ) using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas12a mutants, offering rapid detection, cost-effectiveness, and high specificity, and thereby providing a promising new avenue for detecting isoniazid-resistant Mtb .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidMycobacterium tuberculosisCRISPR-Cas SystemsAntitubercular AgentsDrug Resistance, BacterialEndodeoxyribonucleasesBacterial ProteinsHumansMutationTuberculosis, Multidrug-ResistantClustered Regularly Interspaced Short Palindromic RepeatsCatalaseSensitivity and SpecificityCRISPR-Associated ProteinsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Cas12a_RRclustered regularly interspaced short palindromic repeatsdrug-resistantisoniazidtuberculosis

Substanzen

IsoniazidAntitubercular AgentsBacterial ProteinsCas12a proteinkatG protein, Mycobacterium tuberculosisEndodeoxyribonucleasesCatalaseCRISPR-Associated Proteins

Autor:innen und Institutionen

  • National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
  • Wuhan Pulmonary Hospital, Wuhan Tuberculosis Prevention and Control Institute, The Hubei Branch of the National Clinical Research Center for Infectious Disease, Wuhan, China.
  • Intensive Care Unit, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Clinical Laboratory Experiment Center, Hangzhou Red Cross Hospital, Zhejiang, China.

ORCID-Profile: Guohui Xiao, Guoliang Zhang

Zitieren

APA

Liu, P., Zhang, J., Gong, Y., Liu, W., Xiao, G., Liang, J., Wang, X., Bi, J., & Zhang, G. (2025). Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations in Mycobacterium tuberculosis. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00165-25

Vancouver

Liu P, Zhang J, Gong Y, Liu W, Xiao G, Liang J, et al. Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations in Mycobacterium tuberculosis. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00165-25

BibTeX
@article{Liu2025,
  author = {Liu, Peng and Zhang, Jinping and Gong, Yaqi and Liu, Wenqi and Xiao, Guohui and Liang, Juan and Wang, Xuan and Bi, Jing and Zhang, Guoliang},
  title = {Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations in Mycobacterium tuberculosis},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00165-25}
}
Kostenlos starten →